MedTrace Logo

Improving Iron Levels in Female Endurance, Intermittent, and Power/Strength Athletes Aged 16-35

NCT06942208 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-17

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if different types and doses of oral iron supplements can improve iron levels, athletic performance, and gut health in young female athletes with low iron stores. The main questions it aims to answer are:

* Does a low dose of yeast-bound iron improve iron status better than traditional iron supplements?
* Do the different iron supplements cause fewer or more gastrointestinal (stomach) symptoms?
* How do iron supplements affect exercise performance and gut bacteria?

Researchers will compare three types of iron supplements:

* A low-dose iron supplement (40 mg)
* A low-dose yeast-bound iron supplement (40 mg)
* A high-dose iron supplement (150 mg)

This will help researchers find out which type of supplement is most effective and easiest on the stomach.

Participants will:

* Take one of the three assigned iron supplements every other day for 12 weeks
* Complete fitness tests before and after the study, including cycling and jumping tests
* Give blood samples to measure iron levels
* Provide stool and intestinal samples to study gut bacteria
* Swallow a SIMBA capsule before and after the study to collect a sample from the small intestine
* Complete regular online surveys about sleep, stress, menstrual cycles, and gut symptoms

Conditions

Interventions

DIETARY_SUPPLEMENT

Low-dose iron (ferrous sulfate)

Encapsulated low-dose ferrous sulphate (40mg elemental iron)

DIETARY_SUPPLEMENT

Yeast-bound iron (ferrous sulfate)

Encapsulated yeast-bound low-dose ferrous sulphate (40mg elemental iron)

DIETARY_SUPPLEMENT

High-dose iron (ferrous sulfate)

Encapsulated high-dose ferrous sulphate (150mg elemental iron)

Sponsors & Collaborators

  • Mitacs

    collaborator INDUSTRY

  • Natural Sciences and Engineering Research Council, Canada

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Jane Shearer · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-26
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06942208 on ClinicalTrials.gov